Rapid implementation of home oxygen treatment and remote monitoring for COVID-19 patients at the verge of the Omicron wave in Turku, Finland

Table 5 Cost–benefit assessment of the development and use of the home oxygen treatment and monitoring program

			Costs (-) and savings ( +)
Costs of application
Development costs and usage costs	€ -34 570		€ -34 570
Costs of measurement devices	Per unit	Units (n)
Pulse oximeters	€ 38.49	6	€ -231
Blood pressure monitors	€ 29	6	€ -174
Prevented hospitalization	Per day	Days (n)
In isolation	€ 910	9	€ + 8 190
Not in isolation	€ 850	201.5	€ + 171 275
Total savings—costs			€ + 144 490

Costs are expressed as negative saldo and savings are presented as positive saldo. Due to confidentiallity, costs related to the development and the use of the application could not be further specified. Hospitalization days are the mean value of estimations by two pulmonologists, as described in the methods-section

ISSN: 1471-2334